Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wolinsky, J.S.
Right arrow Articles by Shifroni, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wolinsky, J.S.
Right arrow Articles by Shifroni, G.
Related Collections
Right arrow MRI
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
Right arrow Multiple sclerosis

Neurology 2002;59:1284-1286
© 2002 American Academy of Neurology
Brief Communications

Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained

J.S. Wolinsky, MD, G. Comi, MD, M. Filippi, MD, D. Ladkani, S. Kadosh and G. Shifroni The European/Canadian Glatiramer Acetate Study Group

*See the Appendix for a list of the investigators, roles, and industry affiliations of the members of The European/Canadian Glatiramer Acetate Study Group.
From the University of Texas Health Science Center at Houston (Dr. Wolinsky); the Clinical Trials Unit (Dr. Comi) and the Neuroimaging Research Unit (Dr. Filippi), Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy; and Teva Pharmaceuticals, Ltd. (D. Ladkani, S. Kadosh, and G. Shifroni), Kiryat Nordau, Netanya, Israel.

Address correspondence and reprint requests to Dr. Jerry S. Wolinsky, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030; e-mail: Jerry.S.Wolinsky{at}uth.tmc.edu

All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate.




This article has been cited by other articles:


Home page
 Mult SclerHome page
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al.
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
Multiple Sclerosis, May 1, 2007; 13(4): 502 - 508.
[Abstract] [PDF]

Home page
 NeurologyHome page
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue
The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S3 - S11.
[Abstract] [Full Text]

Home page
 Mult SclerHome page
R. R. Kreitman and F. Blanchette
On the horizon: possible neuroprotective role for glatiramer acetate
Multiple Sclerosis, June 1, 2004; 10(1_suppl): S81 - S89.
[Abstract] [PDF]

Home page
 Mult SclerHome page
R. R. Kreitman and F. Blanchette
On the horizon: possible neuroprotective role for glatiramer acetate
Multiple Sclerosis, May 1, 2004; 10(3_suppl): S81 - S89.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.